Home Delivery

Home Delivery

First 30 days FREE* when eligible patients access Zypitamag through Blink Pharmacy Plus

Please see eligibility criteria below

Insured patients pay as little as


Monthly, after 30 day trial

Cash price reduced from $39 to


Per month for 90 day Rx

  • No pharmacy fees
  • In stock nationwide
  • Prior authorization support
  • Free delivery to patients

Contact Us  Visit Blink Pharmacy

* Maximum benefits and other restrictions apply. Please see full eligibility criteria below. Offer not available for patients who are covered by any federal or state healthcare program.

How it works

1. You prescribe:

E-prescribe Zypitamag™ to Blink Pharmacy Plus U.S. in your EMR's dropdown.

2. Blink will contact your patient:

Blink Pharmacy Plus will contact your patient with a confidential text, determine their copay, assist with prior authorizations and apply savings offers.

3. Zypitamag is delivered to your patients:

Blink Pharmacy Plus will arrange for home delivery and collect payment through their mobile platform or over the phone.

Blink Pharmacy Plus in the EMR

Locate Blink in the EMR

Start by searching for "Blink Pharmacy" in the EMR system's pharmacy search tool

  • Blink Pharmacy is listed as:
    Blink Pharmacy Plus U.S.
  • Blink Pharmacy address:
    3 Penn Center West Suite 320 Pittsburgh, PA 15276
  • Blink Pharmacy Phone:
  • NCPDP Number:


1. Manually add Blink Pharmacy Plus to the EMR

  • Locate the "new" or "add" button in the pharmacy selection screen
  • Input all relevant Blink Pharmacy Plus details and save

If the provider is unable to manually add a pharmacy to the EMR, proceed to Step 2


2. Coordinate with Blink Pharmacy Specialist at 844-963-0320

  • Blink specialist will request the provider's EMR system (i.e. Athena, SRS, Epic)
  • Blink Specialist will coordinate with EMR and provider to load Blink into the system
  • EMR updates may take 24 hours to process
  • Blink Specialist will follow up with provider's office to confirm Blink Pharmacy Plus is visible in the EMR

Details and Eligibility Information for the Blink Health Zypitamag Savings Program

Note that this is the Eligibility criteria for the savings program which is offered through Blink Health Pharmacy Plus. For patients using the Zypitamag Dual Savings Offer please visit https://patient.zypitamag.com/dual-savings-card for eligibility criteria.

Eligibility criteria: This offer is valid for patients who have been prescribed ZYPITAMAG™ for an FDA approved indication and are 18 years of age or older. This offer is valid for the purchase of Zypitamag manufactured for Medicure and lawfully purchased from an authorized retailer or distributor in the United States or its territories. This offer is not valid for any person eligible for reimbursement of prescriptions, by any federal, state, or other government programs, including, but not limited to, Medicare, Medicaid, TRICARE, Veterans Administration or Department of Defense health coverage, the Puerto Rico Government Health Insurance Plan, or any other federal or state health care programs. Patients who move from commercial plans to state or federal healthcare programs will no longer be eligible. The patient is responsible for applicable taxes, if any. This offer is not conditioned on any past, present, or future purchase, including refills. Offer not valid where prohibited by law or restricted. Medicure reserves the right to change or discontinue this offer at any time without notice.

To the patient: By using this offer, you are certifying that you meet the eligibility criteria and will comply with the terms and conditions described herein and will not seek reimbursement for any benefit received through this offer. You are responsible for reporting use of the Blink Health Zypitamag Savings Program to any private insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using this offer. Pharmacy processing will be done through Blink Health's pharmacy platform. Please visit www.blinkhealth.com for more information.

For Commercially Insured Eligible Patients: Pay $0 for your first 30-day prescription. For each subsequent use, this card covers out of pocket costs that exceed $10 per month (up to a maximum of $1,000 per year) on each 30-day supply.

For Commercially Insured Not Covered/Cash Eligible Patients: Pay $0 for your first 30-day prescription. For each subsequent use, the cost for a Zypitamag prescription will be $50.00 for a 30-day supply, $92.00 for a 60-day supply, and $87.00 for a 90-day supply.

For questions relating to the Blink Pharmacy Plus Savings Program for ZYPITAMAG, please call 1-833-977-0504.




ZYPITAMAG is indicated as an adjunctive therapy to diet in adult patients with primary hyperlipidemia or mixed dyslipidemia to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C). Limitations of Use: The effect of ZYPITAMAG on cardiovascular morbidity and mortality has not been determined.

CONTRAINDICATIONS: ZYPITAMAG is contraindicated in patients with a known hypersensitivity to product components, in patients with active liver disease (which may include unexplained persistent elevations in hepatic transaminase levels), in women who are pregnant or may become pregnant, in nursing mothers, or in co-administration with cyclosporine.


  • Myopathy and Rhabdomyolysis: Risk factors include age 65 and greater, renal impairment, inadequately treated hypothyroidism, concomitant use of certain drugs, and higher doses of ZYPITAMAG. ZYPITAMAG is contraindicated in patients taking cyclosporine and not recommended in patients taking gemfibrozil. The following drugs when used concomitantly with ZYPITAMAG may also increase the risk of myopathy and rhabdomyolysis: lipid-modifying dosages of niacin (>1 g/day), fibrates, and colchicine. Discontinue ZYPITAMAG if markedly elevated CK levels occur or myopathy is diagnosed or suspected. Temporarily discontinue ZYPITAMAG in patients experiencing an acute or serious condition at high risk of developing renal failure secondary to rhabdomyolysis; e.g., sepsis; shock; severe hypovolemia; major surgery; trauma; severe metabolic, endocrine, or electrolyte disorders; or uncontrolled epilepsy. Inform patients of the risk of myopathy and rhabdomyolysis when starting or increasing the ZYPITAMAG dosage. Instruct patients to promptly report any unexplained muscle pain, tenderness or weakness particularly if accompanied by malaise or fever.

  • Immune-Mediated Necrotizing Myopathy (IMNM): There have been rare reports of IMNM, an autoimmune myopathy, associated with statin use. IMNM is characterized by: proximal muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents.

  • Hepatic Dysfunction: Increases in serum transaminases can occur. Rare postmarketing reports of fatal and non-fatal hepatic failure have occurred. Consider liver enzyme testing before initiating therapy and as clinically indicated thereafter. If serious hepatic injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs, promptly discontinue ZYPITAMAG.

  • Increases in HbA1c and Fasting Serum Glucose Levels: Increases of each have been reported with statins, including ZYPITAMAG. Optimize lifestyle measures, including regular exercise, maintaining a healthy body weight, and making healthy food choices.

ADVERSE REACTIONS: The most frequent adverse reactions (rate ≥ 2%) are myalgia, back pain, diarrhea, constipation and pain in extremity. This is not a complete list of all reported adverse events.

For additional information, refer to full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

Unite Interactive